ArticleFrontiers in oncology2026
An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: LARC patients exhibit heterogeneity in their response to total neoadjuvant therapy (TNT). This study aims to screen and identify plasma biomarkers associated with treatment response to TNT in patients with locally advanced rectal cancer (LARC) to predict pathological complete response (pCR). Methods: Pre-treatment plasma RNA sequencing and functional annotation were performed in six patients with LARC (three pCR and three non-pCR) to identify differentially expressed genes (DEGs) associated with TNT response. The Olink Results: Compared to the non-pCR group, 365 DEGs were upregulated, and 198 were downregulated in the pCR group. These genes are involved in pathways related to cell growth and death, signal transduction, metabolism, the immune system, insulin secretion, mitophagy, and neutrophil extracellular trap formation. The transcriptomic analysis was conducted in a limited discovery cohort, and these DEGs identified should be interpreted with extreme caution due to the high risk of false discovery. Plasma levels of Fas ligand (FASLG), CD160, andLY6/PLAUR domain containing 3 (LYPD3) in the pCR group were higher than those in the non-pCR group. Receiver operating characteristic (ROC) curve analysis showed that a multi-marker panel consisting of FASLG, CD160, and LYPD3 was superior to three individual indicators in predicting pCR, with an area under the curve (AUC) of 0.791 (95% CI, 0.668-0.885). According to the optimal cutoff value of the multi-marker panel, all LARC patients were stratified into high (n=34, 55.7%) and low (n=27, 44.3%) expression groups. Statistical analysis indicated that high expression group was associated with a higher proportion of EMVI-negative status and a higher pCR rate. High expression of multi-marker was associated with pCR in multivariate analysis. Conclusions: The multi-marker panel consisting of FASLG, CD160, and LYPD3 may serve as a candidate predictor of treatment response in LARC patients undergoing TNT, warranting further validation in larger, multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.